Nano-composite, preparation method thereof and application of nano-composite in preparation of nucleic acid drugs

By using a specific proportion of cationic polyelectrolytes and nanocomplexes of electroneutral/anionic lipid components in nucleic acid drugs, the stability and targeting of nucleic acid drugs in the biological body are solved, and high efficiency and safety are achieved nucleic acid drug delivery avoids the toxicity and immunogenic risks in the prior art.

CN119015225APending Publication Date: 2024-11-26SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310589946.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing delivery systems of nucleic acid drugs in biological organisms have problems such as poor stability, weak targeting and low delivery efficiency, especially the risks of toxicity and immunogenicity of cationic liposomes and lipid nanoparticles.

Method used

Nanocomplexes composed of nucleic acid drugs, cationic polyelectrolytes and electroneutral/anionic lipid components are used to achieve intracellular and in vivo delivery of nucleic acid drugs through appropriate formulations, avoiding the problems of electrostatic adsorption and endosomal escape. , use of electrically neutral and anionic lipids present in nature to improve biocompatibility.

Benefits of technology

It has realized a universal carrier of nucleic acid drugs of different molecular weights, with efficient and safe intracellular and in vivo delivery capabilities, reducing the risk of toxicity and immune response, and expanding the delivery range.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015225A_ABST
    Figure CN119015225A_ABST
Patent Text Reader

Abstract

The invention discloses a nano-composite, a preparation method thereof and application of the nano-composite in preparation of nucleic acid drugs. The nano-composite is prepared from 0.5 to 30 percent of nucleic acid medicine, 0.5 to 95 percent of cationic polyelectrolyte and 1.5 to 97 percent of lipid component, the percentage is the mass percentage of each component relative to the nano-composite; the lipid component comprises electrically neutral lipid and anionic lipid; the electrically neutral lipid is neutral phospholipid containing a primary ammonia head group. The nano-composite comprises a specific amount of nucleic acid medicine, cationic polyelectrolyte and a lipid component which form a microenvironment suitable for the nucleic acid medicine according to a proper proportion; when being used for delivering nucleic acid drugs, the carrier can provide a universal carrier for nucleic acid drugs with different molecular weights, and has good universality and universality; effective intracellular delivery and in-vivo delivery can be realized in various cells, the toxicity is low, and the safety is relatively high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a nanocomposite and a preparation method thereof and application of the nanocomposite in preparing nucleic acid drugs. Background Art

[0002] Chemical small molecules and protein macromolecules dominate pharmaceutical research today. Small molecule drugs (molecular mass less than 900Da) are easy to produce and use but have low specificity. Protein drugs can achieve high specificity in vivo and reduce off-target toxicity through precise design and structural modification of protein engineering technology, but their molecular structure is complex, production costs are high, and patient compliance is poor. Nucleic acid drugs do not directly target proteins, but regulate specific gene expression by inhibiting, adding, replacing or editing at the gene level to produce therapeutic effects. Nowadays, nucleic acid drugs have been used in the clinical treatment of a variety of infectious diseases, chronic metabolic diseases and rare genetic diseases, and are expected to usher in the third wave of new drug creation after small molecules and antibody drugs. Nucleic acid drugs have abundant candidate targets, simple and efficient development processes, stronger specificity than chemical small molecules, and simpler production than protein macromolecules. However, nucleic acid drugs still face many challenges in the complex internal environment of organisms, including poor stability, weak targeting and low delivery efficiency. At present, the lack of a mature delivery system has become the main development bottleneck of nucleic acid drugs. The development of efficient and safe nucleic acid delivery systems has great research significance and clinical transformation value.

[0003] Existing nucleic acid vectors can be divided into viral and non-viral types, each with its own advantages and disadvantages: the representatives of viral vectors are lentivirus and adeno-associated virus, which are currently used for clinical in vitro gene modification and local treatment. The advantages are that the structural proteins can mediate high-level target tissue accumulation of nucleic acids, efficient crossing of cell membranes and rapid release in the cytoplasm, and the disadvantages are that the structural proteins are highly immunogenic, cannot be given multiple times, the nucleic acid load is limited, and there is a risk of insertion mutations in the host genome; non-viral vectors are mainly nanoparticles formed by lipids, peptides or polymers alone or in combination. Currently, lipid nanoparticles (LNPs) based on cationic / ionizable lipids are available for clinical application. In previous studies, Professor Huang Lifu's research group invented a cationic liposome-polycation-hyaluronic acid nanocomplex, which can achieve tumor-specific delivery of nucleic acid drugs under the mediation of targeting groups on the surface of the nanocomplex. However, lipid nanoparticles (LNPs) and cationic liposome-polycation-hyaluronic acid nanocomplexes are both delivery systems based on cationic / ionizable lipids, which have toxicity and immunogenicity risks. For example, intravenous administration of cationic liposomes can cause liver damage and induce a strong interferon-γ response in mice, leading to inflammation. PEGylated lipids in formulations are also known to induce allergic reactions. Summary of the invention

[0004] The technical problem to be solved by the present invention is to overcome the lack of a carrier method suitable for nucleic acid drugs in the prior art to achieve safe and efficient intracellular and in vivo targeted delivery thereof, and to provide a nanocomplex and a preparation method thereof and an application thereof in the preparation of nucleic acid drugs. The nanocomplex of the present invention comprises a specific amount of nucleic acid drugs, cationic polyelectrolytes and lipid components, which form a microenvironment suitable for nucleic acid drugs through a suitable ratio; when used to deliver nucleic acid drugs, it can not only provide a universal carrier for nucleic acid drugs of different molecular weights, but also has good versatility and universality; it can also achieve effective intracellular delivery and in vivo delivery in a variety of cells, with low toxicity and high safety.

[0005] The present invention solves the above technical problems through the following technical solutions.

[0006] The first object of the present invention is to provide a nanocomposite, wherein the nanocomposite comprises 0.5-30% nucleic acid drug, 0.5-95% cationic polyelectrolyte and 1.5-97% lipid component; the above percentages are the mass percentages of each component relative to the nanocomposite:

[0007] The lipid components include electrically neutral lipids and anionic lipids; the electrically neutral lipids are neutral phospholipids containing primary amino head groups.

[0008] Based on the negative charge characteristics of nucleic acid molecules, since neutral lipids and anionic lipids cannot electrostatically adsorb negatively charged nucleic acids, nor can they bind to endosomal membranes through electrostatic action, those skilled in the art usually use positively charged ionizable lipids or cationic lipids, which can not only encapsulate nucleic acids through electrostatic adsorption, but also bind to negatively charged endosomal membranes after entering the endosomes and produce membrane disturbances, promoting the escape of loaded nucleic acids from the endosomes, thereby solving the difficult problems of nucleic acid encapsulation and endosomal escape during the delivery of nucleic acid drugs. The present invention takes a different approach, and solves the technical problems that the prior art must solve through ionizable lipids or cationic lipids through the above-mentioned formula, and in the present invention, the cationic lipids may not be included in the nanocomplex.

[0009] In the present invention, the nucleic acid drug may be a conventional nucleic acid drug in the art, preferably one or more of siRNA, mRNA, sgRNA, pDNA, ASO and miRNA, more preferably one or more of mRNA, siRNA and pDNA, such as mRNA, siRNA or pDNA.

[0010] In some preferred embodiments, the following model nucleic acid drugs are used:

[0011]

[0012] Wherein, EGFP refers to Enhanced Green Fluorescent Protein, specifically refers to enhanced green fluorescent protein; EGFPpDNA, EGFP siRNA and EGFP mRNA are all commercially available.

[0013] Luc refers to Luciferase, specifically luciferase; Luc mRNA is commercially available.

[0014] In the present invention, the cationic polyelectrolyte generally refers to a polyelectrolyte in which the positive charge is greater than the negative charge in the solution and the overall solution shows a positive charge property outwardly, preferably a cationic polypeptide and / or a cationic protein.

[0015] Wherein, the cationic polypeptide is preferably an oligoarginine polypeptide, more preferably one or more of octaarginine cyclic peptide (CR8C), octaarginine linear peptide (R8), decaarginine linear peptide (R10) and 15-arginine linear peptide (R15), such as octaarginine cyclic peptide (CR8C), octaarginine linear peptide (R8), decaarginine linear peptide (R10) or 15-arginine linear peptide (R15). The use of oligoarginine polypeptides with lower immunogenicity as cationic polypeptides can effectively reduce the body's immune response to the carrier and achieve high-dose and multi-frequency administration of nucleic acids in vivo.

[0016] Wherein, the cationic protein is preferably protamine.

[0017] The protamine is preferably one or more of monoprotamine, diprotamine, ternary protamine and protamine hydrolysate; more preferably one or more of monoprotamine sulfate and its derivatives.

[0018] In the present invention, the electrically neutral lipid generally refers to a lipid in which positive and negative ions are balanced in an electrically neutral solution, and the overall solution does not show the property of being charged outward. In the neutral phospholipid containing a primary amino head group, the primary amino head group refers to a group generated by replacing a hydrogen atom in an ammonia molecule, and the general formula is: R-NH2.

[0019] In the present invention, the neutral phospholipid containing a primary amino head group is preferably dimyristoylphosphatidylethanolamine (DMPE), distearoylphosphatidylethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), dihexanoylphosphatidylethanolamine (06:0PE), didecanoylphosphatidylethanolamine (10:0PE), dilauroylphosphatidylethanolamine (12:0PE), 1-palmitoyl-2-oleoylphosphatidylethanolamine (16:0-18:1 PE), 1-stearoyl-2-oleoylphosphatidylethanolamine (18:0-18:1 PE), dilinoleoylphosphatidylethanolamine (18:2PE) and one or more of their derivatives.

[0020] In the present invention, the anionic lipid generally refers to a lipid whose negative charge is greater than its positive charge in a solution, and the entire solution exhibits a negative charge property outwardly, and is preferably anionic phospholipids.

[0021] The anionic phospholipid is preferably one or more of phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, cardiolipin, lysophospholipid and ganglioside, more preferably phosphatidic acid, phosphatidylglycerol or phosphatidylserine.

[0022] The phosphatidic acid is preferably one or more of dimyristoylphosphatidic acid (DMPA), distearoylphosphatidic acid (DSPA), dipalmitoylphosphatidic acid (DPPA), dioleoylphosphatidic acid (DOPA), dihexanoylphosphatidic acid (06:0PA), didecanoylphosphatidic acid (10:0PA), dilauroylphosphatidic acid (12:0PA), 1-palmitoyl-2-oleoylphosphatidic acid (16:0-18:1 PA), 1-stearoyl-2-oleoylphosphatidic acid (18:0-18:1 PA), dilinoleoylphosphatidic acid (18:2PA), soybean phosphatidic acid (SOYPA) and their derivatives, such as dioleoylphosphatidic acid (DOPA).

[0023] The phosphatidylglycerol is preferably dimyristoylphosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylglycerol (DOPG), dihexanoylphosphatidylglycerol (06:0PG), didecanoylphosphatidylglycerol (10:0PG), dilauroylphosphatidylglycerol (12:0PG), 1-palmitoyl-2-oleoylphosphatidylglycerol (16:0-18:1PG), 1-stearoyl-2-oleoylphosphatidylglycerol (18:0-18:1 PG), dilinoleoylphosphatidylglycerol (18:2PG), egg yolk phosphatidylglycerol (EPG) and one or more of their derivatives, such as dioleoylphosphatidylglycerol (DOPG).

[0024] The phosphatidylserine is one or more of dimyristoylphosphatidylserine (DMPS), dioleoylphosphatidylserine (DOPS), dipalmitoylphosphatidylserine (DPPS), dihexanoylphosphatidylserine (06:0PS), didecanoylphosphatidylserine (10:0PS), dilauroylphosphatidylserine (12:0PS), 1-palmitoyl-2-oleoylphosphatidylserine (16:0-18:1 PS), 1-stearoyl-2-oleoylphosphatidylserine (18:0-18:1 PS), dilinoleoylphosphatidylserine (18:2PS) and distearoylphosphatidylserine (DSPS), such as dioleoylphosphatidylserine (DOPS).

[0025] In the present invention, electrically neutral lipids and anionic lipids existing in nature are used, which have high biocompatibility, achieve higher delivery efficiency, better safety, and a wider range of nucleic acid drugs to be delivered.

[0026] In the present invention, the nanocomposite may further include anionic polyelectrolytes. The anionic polyelectrolytes generally refer to polyelectrolytes in which the negative charge is greater than the positive charge in the solution and the entire solution shows negative charge properties outwardly, preferably glycosaminoglycan and / or alginic acid.

[0027] The glycosaminoglycan is preferably one or more of heparin, hyaluronic acid (HA), chondroitin sulfate, keratan sulfate and dermatan sulfate, and more preferably heparin and / or hyaluronic acid.

[0028] The heparin is preferably one or more of ordinary heparin UFH, low molecular weight heparin LMWH, heparin derivatives, heparin analogs and derivatives thereof; the low molecular weight heparin is preferably dalteparin sodium; the heparin derivative is preferably fondaparinux sodium; the heparin analog is preferably danaparin.

[0029] The hyaluronic acid is preferably one or more of hyaluronate, oligomeric hyaluronic acid, non-crosslinked hyaluronic acid, crosslinked hyaluronic acid and derivatives thereof, such as hyaluronate. In the present invention, "and derivatives thereof" refers to derivatives of all exemplified components. The molecular weight of the hyaluronate is preferably 3 to 2200 kDa, such as 10 kDa, 50 kDa, 70 kDa, 100 kDa, 210 kDa, 700 kDa or 2200 kDa.

[0030] In the present invention, preferably, the nanocomplex does not include PEGylated phospholipids. PEGylated phospholipids refer to phosphatidylethanolamine that has been chemically modified after being conjugated with polyethylene glycol chains.

[0031] In the present invention, preferably, the nanocomplex does not include apolipoprotein and / or its mimetic peptide.

[0032] In the present invention, the dosage of the nucleic acid drug can be 0.5-10%, for example, 0.83%, 1.41%, 1.50%, 1.52%, 2.19%, 2.63%, 2.72%, 2.75%, 3.00%, 3.26%, 3.38%, 3.44%, 3.48%, 3.74%, 3.89%, 4.05%, 4.22%. , 4.29%, 4.34%, 4.36%, 4.40%, 4.41%, 4.44%, 4.46%, 4.48%, 4.52%, 4.53%, 4.54%, 4.59%, 4.61%, 4.62%, 4.64%, 5.34%, 5.77%, 6.52%, 6.97%, 6.98% or 9.37%.

[0033] In the present invention, the amount of the cationic polyelectrolyte can be 1 to 90%, preferably 4 to 75%, for example 4.14%, 7.07%, 7.59%, 10.69%, 10.94%, 13.13%, 13.73%, 14.99%, 16.28%, 17.20%, 17.41%, 18.72%, 19.45%, 20.23%, 21.09%, 21.43%, 21.68%, 21.8 0%, 22.00%, 22.01%, 22.05%, 22.21%, 22.31%, 22.42%, 22.56%, 22.58%, 22.63%, 22.71%, 22.94%, 23.03%, 23.07%, 23.12%, 23.21%, 28.84%, 32.61%, 34.83%, 34.88%, 46.83%, 54.48% or 74.95%.

[0034] In the present invention, the mass ratio of the cationic polyelectrolyte to the nucleic acid drug may be (2-50):1, such as 2:1, 5:1, 20:1 or 50:1.

[0035] Among them, preferably, the cationic polyelectrolyte is CR8C, and the mass ratio of CR8C to the nucleic acid drug is 5:1.

[0036] Preferably, the cationic polyelectrolyte is Protamine, and the mass ratio of Protamine to the nucleic acid drug is 2:1.

[0037] In the present invention, the mass ratio of the lipid component to the nucleic acid drug can be (3-60):1, for example, 3.68:1, 7.33:1, 7.34:1, 7.35:1, 7.58:1, 14.55:1, 14.64:1, 14.67:1, 14.68:1, 14.69:1, 14.70:1, 14.71:1, 14.72:1, 14.74:1, 14.76:1 ∶1, 14.79∶1, 14.89∶1, 15.02∶1, 15.08∶1, 15.13∶1, 15.19∶1, 15.32∶1, 15.35∶1, 15.42∶1, 15.52∶1, 15.67∶1, 15.73∶1, 15.94∶1, 16.05∶1, 22.07∶1, 29.37∶1, 31.03∶1 or 58.80∶1.

[0038] In the present invention, when the nanocomposite includes an anionic polyelectrolyte, the amount of the anionic polyelectrolyte may be 0 to 95% and is not 0, preferably 1.5 to 90%, more preferably 1.5 to 85%, for example 1.5%, 1.52%, 2.63%, 2.72%, 2.75%, 3.44%, 4.34%, 4.36%, 4.40%, 4.41%, 4.44%, 4.46%, 4.48%, 4.52%, 4.53%, 4.54%, 4.59%, 4.61%, 4.62%, 4.64%, 5.34%, 6.97%, 6.98%, 8.81%, 8.82%, 9.37%, 12.65%, 13.04%, 16.19%, 19.45%, 22.46%, 23.07%, 27.86%, 32.56%, 42.85%, 54.69%, 59.96%, 67.63%, 70.71% or 82.84%.

[0039] In the present invention, when the nanocomposite includes anionic polyelectrolytes, the total amount of the anionic polyelectrolytes and cationic polyelectrolytes can be 9-90%, for example, 9.11%, 13.41%, 15.76%, 16.03%, 16.48%, 20.64%, 26.02%, 26.16%, 26.40%, 26.46%, 26.65%, 26.71%, 26.77%, 26.90%, 27.03%, 27.10%, 27.16%, 27.25%, 27.49%, 27. 53%, 27.64%, 27.68%, 27.74%, 27.85%, 30.82%, 31.38%, 33.74%, 36.42%, 38.90%, 41.18%, 41.80%, 41.86%, 45.27%, 45.65%, 48.84%, 51.91%, 55.98%, 56.20%, 57.20%, 59.09%, 64.28%, 65.63%, 67.63%, 74.95%, 76.45%, 77.78% or 86.95%.

[0040] In the present invention, when the nanocomplex includes anionic polyelectrolytes, the mass ratio of the anionic polyelectrolyte to the nucleic acid drug can be (1-100):1, for example, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 8:1, 10:1, 25:1, 50:1 or 100:1, preferably 2:1.

[0041] In the present invention, the amount of the anionic lipid can be 4-70%, for example, 4.79%, 5.48%, 7.36%, 8.18%, 8.67%, 12.65%, 13.27%, 13.54%, 14.43%, 14.63%, 15.49%, 15.76%, 18.83%, 20.14%, 20.85%, 21.65%, 22.50%, 23.41%, 23.57%, 24.39%, 24.39%, 25.22%, 25.47%, 26.64%, 28.59%, 28.92%, 29.85%, 30.91%, 31.76%, 31.89%, 33.36%, 35.14%, 40.11%, 42.48%, 42.54%, 42.87%, 53.69%, 56.11% or 63.20%.

[0042] In the present invention, the molar ratio of the anionic lipid to the lipid component may be (10-90):100, such as 10:100, 20:100, 40:100, 60:100, 80:100 or 90:100.

[0043] Among them, preferably, the anionic lipid is DOPA, and the molar ratio of DOPA to the lipid component is (20-80):100, preferably (40-80):100, for example 40:100.

[0044] Among them, preferably, the anionic lipid is DOPS, and the molar ratio of DOPS to the lipid component is (10-80):100, preferably (20-60):100, for example 20:100.

[0045] Among them, preferably, the anionic lipid is DOPG, and the molar ratio of DOPG to the lipid component is (20-80):100, preferably (20-60):100, such as 40:100.

[0046] In the present invention, the amount of the electrically neutral lipid can be 6-70%, for example, 6.45%, 7.40%, 12.63%, 12.98%, 13.09%, 13.38%, 13.81%, 15.94%, 19.53%, 20.13%, 20.90%, 21.46%, 24.26%, 24.32%, 25.95%, 26.43%, 27.52%, 28. 9.07%, 31.1%, 32.82%, 33.42%, 34.33%, 34.72%, 36.13%, 37.65%, 39.08%, 39.31%, 39.84%, 40.03%, 41.12%, 46.07%, 47.71%, 49.02%, 53.76%, 53.88%, 54.23%, 54.62 or 62.84%.

[0047] In the present invention, the particle size of the nanocomposite may be 100 to 3500 nm, for example, 110.9 nm, 125.6 nm, 129.6 nm, 133.9 nm, 134.1 nm, 135.2 nm, 135.9 nm, 136.0 nm, 141.3 nm, 142.7 nm, 147.5 nm, 147.6 nm, 150.2 nm, 152.2 nm, 152. 3nm, 156.8nm, 157.9nm, 165.9nm, 172.3nm, 178.3nm, 181.3nm, 184.4nm, 188.5nm, 192.7 nm, 193.2nm, 196.3nm, 197.2nm, 226.1nm, 253.8nm, 529.9nm, 542.6nm, 576.9nm, 648.9n m, 860.2nm, 874.3nm, 874.9nm, 896.7nm, 897.3nm, 897.5nm, 932.7nm, 974.4nm, 987.3nm , 989.5nm, 1014nm, 1035nm, 1058nm, 1088nm, 1090nm, 1095nm, 1098nm, 1133nm, 1187nm, 1 195nm, 1196nm, 1277nm, 1284nm, 1320nm, 1328nm, 1337nm, 1374nm, 1438nm, 1455nm, 1464nm, 1548nm, 1569nm, 1648nm, 1692nm, 1778nm, 1876nm, 1976nm, 2080nm, 2267nm or 3370nm.

[0048] In the present invention, the zeta potential of the nanocomposite may be -50 to +40 mV, for example, -44.9 mV, -43.2 mV, -38.9 mV, -37.9 mV, -32.5 mV, -32.2 mV, -31.8 mV, -31.2 mV, -30.5 mV, -29.4 mV, -27.8 mV, -27.6 mV, -27.3 mV, -25.6 mV, -25.1 mV, -24.1mV, -23.7mV, -22.8mV, -21.9mV, -21.8mV, -20.9mV, -20.5mV, -20.2mV, -18.1mV, -17. 8mV, -16.4mV, -15.3mV, -13.2mV, -12.2mV, -11.6mV, -11.0mV, -10.5mV, -9.84mV, -8.90mV, - 7.82mV, -5.30mV, -5.05mV, -4.78mV, -4.76mV, -4.3mV, -3.21mV, -3.2mV, -3.06mV, -2.97mV , -2.76mV, -2.66mV, -2.50mV, -2.40mV, -2.31mV, -2.1mV, -1.46mV, -1.45mV, -1.32mV, -1.28 mV, -0.686mV, 0.843mV, 0.90mV, 0.98mV, 1.29mV, 1.30mV, 1.40mV, 1.57mV, 1.89mV, 2.10mV, 2 .80mV, 3.17mV, 3.28mV, 4.79mV, 5.58mV, 8.43mV, 14.77mV, 35.4mV, 35.5mV, 36.9mV or 37.9mV.

[0049] The second object of the present invention is to provide a method for preparing the nanocomposite, which is prepared by the following method 1, method 2, method 3, method 4 or method 5:

[0050] Method 1:

[0051] S1. The nucleic acid drug and the cationic polyelectrolyte are mixed to form a nucleic acid-loaded complex;

[0052] S2. preparing liposomes by conventional methods using the lipid components;

[0053] S3. The nucleic acid-loaded complex is co-incubated with the liposome to form a nucleic acid-loaded nanocomplex;

[0054] Method 2:

[0055] S1. The nucleic acid drug and the cationic polyelectrolyte are mixed to form a nucleic acid-loaded complex;

[0056] S2. preparing liposomes by conventional methods using the lipid components;

[0057] S3. The nucleic acid-loaded complex and the liposome are prepared by a microfluidic chip to carry out a nucleic acid-loaded nanocomposite;

[0058] Method 3:

[0059] S1. The nucleic acid drug and the cationic polyelectrolyte are mixed to form a nucleic acid-loaded complex;

[0060] S2. preparing liposomes by conventional methods using the lipid components;

[0061] S3. The nucleic acid-loaded complex and the liposome are extruded through a membrane to prepare a nucleic acid-loaded nanocomplex;

[0062] Method 4:

[0063] S1. The nucleic acid drug and the anionic polyelectrolyte are mixed in DEPC water;

[0064] S2. The lipid component and the cationic polyelectrolyte are mixed in ethanol;

[0065] S3. The aqueous phase and the alcohol phase are mixed to form a nanocomplex loaded with nucleic acid;

[0066] Method 5:

[0067] S1. The nucleic acid drug and the cationic polyelectrolyte are mixed to form a nucleic acid-loaded complex;

[0068] S2. dissolving the lipid component in ethanol;

[0069] S3. The nucleic acid-loaded complex is mixed with a lipid ethanol solution to form a nucleic acid-loaded nanocomplex.

[0070] In methods 1 to 5, in S1, the raw materials during the mixing may further include the anionic polyelectrolyte.

[0071] In method 1 or method 2, in S1, the mixing operation and method may be conventional in the art.

[0072] In method one or method two, in S2, the conventional method may be a conventional liposome preparation method in the art, such as a thin film hydration method, an injection method, a microfluidics method, a reconstitution method, a melting method or a freeze-drying method.

[0073] As a preferred embodiment, in method 1, S2, the liposomes can be prepared by the following steps: the lipid component is dissolved in an organic solvent, and then the solvent is evaporated on a rotary evaporator to form a thin film on the wall of the evaporator, and then an appropriate amount of buffer solution is added, and the liposomes are fully hydrated and dispersed by shaking to obtain liposomes. The particle size of the liposomes can be further reduced by ultrasound using an ultrasound probe.

[0074] In method 1, S3, the incubation operation and method can be conventional in the art. In the present invention, the incubation refers to the operation of mixing lipids and nucleic acid-loaded complexes at a specific temperature to self-assemble to form nanocomplexes.

[0075] In method 2, S3, the method of preparing liposomes containing nucleic acid-loaded complexes by using the nucleic acid-loaded complexes and the liposomes through a microfluidic chip can be a conventional method in the art. In the present invention, microfluidic chip technology is a technology for manipulating or controlling microfluids by using micrometer-scale flow channels, which relies on the use of a microfluidic device with a cross-flow geometry to trigger the formation of liposomes through a self-assembly mechanism.

[0076] Method 2, S3, may further include an ultrafiltration operation. The ultrafiltration may remove the solvent.

[0077] In method three, S3, the membrane extrusion method can be conventional in the art. In the present invention, the membrane extrusion technology is to pass the liposome through a polycarbonate membrane with a specific pore size under a condition slightly higher than the phase transition temperature of phospholipids by a certain external extrusion force, and the large-size or multi-chamber liposomes are sheared and ruptured by the membrane pores and then quickly repolymerized into liposomes with smaller particle sizes. After multiple extrusion and shearing of the polycarbonate membrane with a specific pore size, a single-chamber liposome with a particle size close to the pore size of the polycarbonate membrane and concentrated distribution can be obtained.

[0078] Method 4, in S1, DEPC water refers to ultrapure water treated with DEPC (diethyl pyrocarbonate) and sterilized by high temperature and high pressure, and does not contain impurities such as RNA, DNA and protein.

[0079] In method 4, in S3, the method of mixing the water and alcohol can be conventional in the art.

[0080] As a preferred solution, in method 4, S3, the nanocomplex can be prepared by the following steps: injecting the aqueous phase into the alcohol phase, mixing by pipetting, and incubating at room temperature for 10 minutes; and preparing by microfluidic chip.

[0081] The third object of the present invention is to provide a use of the nanocomplex in the preparation of nucleic acid drugs.

[0082] In the present invention, the nucleic acid drug can be delivered to cells or in vivo.

[0083] The cells may be HEK293T cells, SH-SY5Y cells, HT-22 cells, HepG2 cells, BV2 cells, bEnd.3 cells, U87 cells, GL261 cells, U2OS cells or HT1080 cells.

[0084] In the present invention, unless otherwise specified, "%" refers to mass percentage.

[0085] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0086] The reagents and raw materials used in the present invention are commercially available.

[0087] The positive and progressive effects of the present invention are:

[0088] The nanocomplex of the present invention comprises a specific amount of nucleic acid drugs, cationic polyelectrolytes and lipid components, which constitute a microenvironment suitable for nucleic acid drugs through appropriate proportions; when used for delivering nucleic acid drugs, it can not only provide a universal carrier for nucleic acid drugs of different molecular weights, and has good versatility and universality; it can also achieve effective intracellular delivery and in vivo delivery in a variety of cells, with low toxicity and high safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0089] Figure 1 The transfection effect of the nanocomplex in Example 1 on HEK293T cells. Figure 1 Part (A) is a nanocomplex containing different anionic phospholipids. Figure 1 Part (B) is the control group of nanocomplexes.

[0090] Figure 2 This is the transfection effect of the nanocomplex in Example 2 on HEK293T cells.

[0091] Figure 3 The transfection effect of the nanocomplex on HEK293T cells in Example 3. Figure 3 Part (A) is a nanocomposite containing different proportions of DOPA. Figure 3 Part (B) is a nanocomposite containing different proportions of DOPS. Figure 3 Part (C) shows nanocomposites containing different proportions of DOPG.

[0092] Figure 4 The transfection effect of the nanocomplex containing different cationic polyelectrolytes on HEK293T cells in Example 4. Figure 4 Part (A) is a nanocomplex containing octa-arginine cyclic peptide CR8C. Figure 4Part (B) is a nanocomplex containing protamine sulfate.

[0093] Figure 5 The figure shows the transfection effect of the nanocomplexes using poly-arginine with different polymerization degrees as cationic polyelectrolyte in Example 5 on HEK293T cells.

[0094] Figure 6 The transfection effect of the nanocomplex containing different anionic polyelectrolytes on HEK293T cells in Example 6. Figure 6 Part (A) is a nanocomposite containing hyaluronate HA, Figure 6 Part (B) is a nanocomplex containing dalteparin sodium.

[0095] Figure 7 The figure shows the transfection effect of the nanocomplexes with hyaluronic acid HA of different polymerization degrees as anionic polyelectrolyte on HEK293T cells in Example 7.

[0096] Figure 8 This is the transfection effect of the nanocomplex in Example 8 in different cells.

[0097] Fig. 9 The transfection effect of the nanocomplex loaded with different nucleic acid drugs in Example 9. Fig. 9 Part (A) shows the transfection effect of the nanocomplex loaded with EGFP siRNA on U2OS cells. Fig. 9 Part (B) shows the transfection effect of the nanocomplex loaded with EGFPpDNA on HEK293T cells.

[0098] Fig.10 The transfection effect of the anionic phospholipid nanocomplex and ionizable phospholipid lipid nanoparticles on HEK293T cells in Example 10 ( Fig.10 (A)) and toxic effects ( Fig.10 (B) of the .

[0099] Fig.11 The nanocomplexes loaded with Luc mRNA in Example 11 were intraperitoneally injected into BALB / c nude mice ( Fig.11 (A)), intravitreal injection ( Fig.11 (B)), intramuscular injection ( Fig.11 (C)) and stereotaxic injection ( Fig.11 Luminescence signal distribution in (D). DETAILED DESCRIPTION

[0100] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0101] 1. In the following examples, the following model nucleic acid drugs are used:

[0102]

[0103] 2. In the following embodiments,

[0104] (1) When the nucleic acid loaded is EGFP mRNA and EGFP pDNA and the cells are HEK293T, the greater the EGFP positive cell rate (the proportion of cells expressing EGFP to all cells), the higher the transfection efficiency. The average fluorescence intensity of EGFP indirectly reflects the amount of EGFP expressed. The more EGFP is expressed, the greater the average fluorescence intensity.

[0105] (2) When the nucleic acid loaded is EGFP siRNA and the cells are U2OS, the EGFP positive cell rate cannot reflect the transfection efficiency. The average fluorescence intensity of EGFP indirectly reflects the amount of EGFP expressed. The more EGFP is expressed, the greater the average fluorescence intensity, and the lower the transfection efficiency.

[0106] Example 1 Preparation, characterization and in vitro transfection of nanocomplexes with different formulations

[0107] (1) Preparation method 1:

[0108] ① The octa-arginine cyclic peptide CR8C, EGFP mRNA, and hyaluronate HA (70kDa) were co-incubated at a certain mass ratio to form a nucleic acid-loaded complex (EGFP mRNA-HA-CR8C).

[0109] ②Prepare liposomes by thin film hydration method: weigh phospholipids (neutral lipids DOPE or DMPC and anionic phospholipids DOPA, DOPS or DOPG), place in a 500mL round-bottom flask, add 2mL of ether, evaporate to remove water from phospholipids, add 2mL of chloroform solution, and place on a rotary evaporator to evacuate for 1 hour. Add 4mL of DEPC water and shake for 10 minutes until the phospholipid film is hydrated and detached to obtain liposomes. Ultrasonic probe ultrasound further reduces the liposome particle size to obtain liposomes (LIPO).

[0110] ③ The liposomes were co-incubated with EGFP mRNA-HA-CR8C in different proportions to form nanocomplexes encapsulating nucleic acid drugs (EGFP mRNA-HA-CR8C-LIPO).

[0111] (2) Characterization

[0112] The particle size and surface potential were measured by laser particle size analyzer.

[0113] (3) Evaluation of intracellular transfection effect

[0114] The experimental group and the control group (EGFP mRNA administration concentration was 2 μg / mL) were co-incubated with HEK293T cells at 37°C for 24 h. The transfection effect of the nanocomplex loaded with EGFP mRNA on HEK293T cells was observed by fluorescence microscopy, and the EGFP positive cell rate and mean fluorescence intensity were quantitatively counted by flow cytometry.

[0115] Experimental group: DOPA, DOPS or DOPG were used as anionic phospholipids to prepare nanocomplexes EGFP mRNA-HA-CR8C-LIPO (numbered A01 to A03).

[0116] Control group: ①EGFP mRNA: free nucleic acid drug (No. B01); ②EGFP mRNA-HA-CR8C: without lipid components (No. B02); ③EGFP mRNA-LIPO: EGFP mRNA phospholipid mixture without HA and CR8C (No. B03~B05); ④ Nanocomplex with DMPC as neutral phospholipid in EGFP mRNA-HA-CR8C-LIPO (No. B06).

[0117] The test results are shown in Table 1. Figure 1 Part (A) and Figure 1 As shown in part (B).

[0118] Table 1 Quantitative results of nanocomposites with different formulations

[0119]

[0120]

[0121] The results showed that the particle size of EGFP mRNA-HA-CR8C-LIPO was large and electrically neutral. According to the EGFP positive cell rate and the average fluorescence intensity of EGFP, EGFP mRNA-HA-CR8C-LIPO was more effective in transfecting HEK293T cells than EGFP mRNA, EGFP mRNA-HA-CR8C and EGFP mRNA-LIPO. At the same time, the EGFP mRNA-HA-CR8C-LIPO nanocomplexes formed by different anionic lipids DOPA, DOPS or DOPG could achieve transfection, and the transfection efficiency of the nanocomplexes with DOPA as the anionic phospholipid was higher than that of the nanocomplexes with DOPS or DOPG as the anionic phospholipids. However, when the neutral phospholipid was DMPC, the transfection effect was poor.

[0122] Example 2 Preparation, characterization and in vitro transfection of nanocomplexes with different formulations

[0123] (1) Preparation of Method 4:

[0124] ① EGFP mRNA and hyaluronate HA (70 kDa) were mixed in DEPC water at a fixed mass ratio (1:1).

[0125] ② Mix the octa-arginine cyclic peptide CR8C and phospholipids (neutral lipid DOPE and anionic phospholipid DOPA) in an ethanol solution.

[0126] ③ According to the volume ratio of water phase:alcohol phase = 4:1 and the total flow rate of 5 mL / min, a nanocomplex loaded with nucleic acid drugs was formed through a microfluidic chip.

[0127] (2) Characterization

[0128] The particle size and surface potential were measured by laser particle size analyzer.

[0129] (3) Evaluation of in vitro transfection effect

[0130] The experimental group and the control group (EGFP mRNA administration concentration was 2 μg / mL) were incubated with HEK293T cells at 37°C for 24 h. The transfection effect of the nanocomplex loaded with EGFP mRNA on HEK293T cells was observed by fluorescence microscopy, and the positive cell rate and mean fluorescence intensity were quantitatively counted by flow cytometry.

[0131] Experimental group: DOPA was used as anionic phospholipid, and the lipid component / EGFP mRNA (wt / wt) = 14.7 was used to prepare the nanocomplex EGFP mRNA-HA-CR8C-LIPO (No. A04).

[0132] Control group: ①EGFP mRNA-HA-CR8C: without lipid components (No. B07); ②EGFP mRNA-LIPO: EGFP mRNA phospholipid mixture without HA and CR8C (No. B08).

[0133] The test results are shown in Table 2. Figure 2 shown.

[0134] Table 2 Quantitative results of nanocomposites with different formulations

[0135]

[0136] The results showed that the transfection effect of EGFP mRNA-LIPO was poor; the transfection effect of EGFP mRNA-HA-CR8C was poor, and the addition of lipid components could achieve high-level transfection (EGFP mRNA-HA-CR8C-LIPO).

[0137] Example 3 Preparation, characterization and in vitro transfection of nanocomplexes containing different anionic phospholipid ratios

[0138] (1) Preparation method 1:

[0139] ① The octa-arginine cyclic peptide CR8C, EGFP mRNA, and hyaluronate HA (70 kDa) were incubated at a fixed mass ratio (5:1:1) to form a nucleic acid-loaded complex (EGFP mRNA-HA-CR8C).

[0140] ②Prepare liposomes by thin film hydration method: Weigh lipids (neutral phospholipids DOPE and anionic phospholipids DOPA, DOPS or DOPG), place in a 500mL round-bottom flask, add 2mL of ether, evaporate to remove water from phospholipids, add 2mL of chloroform solution, and place on a rotary evaporator to evacuate for 1h. Add 4mL of DEPC water and shake for 10min until the thin film is hydrated and falls off to obtain liposomes. Ultrasonication with the ultrasonic probe further reduces the particle size of liposomes to obtain liposomes (LIPO).

[0141] ③ Liposomes with different anionic phospholipid ratios were co-incubated with EGFP mRNA-HA-CR8C to prepare nanocomplexes encapsulating nucleic acid drugs (EGFP mRNA-HA-CR8C-LIPO).

[0142] (2) Characterization

[0143] The particle size and surface potential were measured by laser particle size analyzer.

[0144] (3) Evaluation of in vitro transfection effect

[0145] The experimental group and the control group (EGFP mRNA administration concentration was 2 μg / mL) were co-incubated with HEK293T cells at 37°C for 24 h. The transfection effect of the nanocomplex loaded with EGFP mRNA on HEK293T cells was observed by fluorescence microscopy, and the EGFP positive cell rate and mean fluorescence intensity were quantitatively counted by flow cytometry.

[0146] Experimental group: DOPA, DOPS or DOPG were used as anionic phospholipids to prepare nanocomplexes EGFP mRNA-HA-CR8C-LIPO (numbered A05 to A18).

[0147] Control group: ①EGFP mRNA-HA-CR8C: does not contain lipid components (No. B09); ②EGFP mRNA-LIPO: EGFP mRNA phospholipid mixture without HA and CR8C (No. B10~B27); ③EGFP mRNA-HA-CR8C-LIPO does not contain anionic phospholipids (No. B28); ④EGFP mRNA-HA-CR8C-LIPO does not contain electrically neutral lipids (No. B29~B31).

[0148] The test results are shown in Table 3. Figure 3 Part (A) Figure 3 Part (B) and Figure 3 As shown in part (C).

[0149] Table 3 Quantitative results of nanocomplexes containing different anionic phospholipid ratios

[0150]

[0151]

[0152] The results showed that the transfection effect of EGFP mRNA-LIPO was poor; for EGFP mRNA-HA-CR8C-LIPO, the transfection effect of prescriptions with different anionic phospholipid ratios on HEK293T cells showed great differences, and the transfection efficiency showed a trend of first increasing and then decreasing with the increase of anionic lipids. When the anionic lipid / lipid component (mol / mol) was in the range of (10-90):100, it had a better transfection effect. When the anionic phospholipid was DOPA, the DOPA / lipid component (mol / mol) had the highest transfection effect in the range of (40-80):100; when the anionic phospholipid was DOPS, the DOPS / lipid component (mol / mol) had the highest transfection effect in the range of (20-60):100; when the anionic phospholipid was DOPG, the DOPG / lipid component (mol / mol) had the highest transfection effect in the range of (20-60):100.

[0153] Example 4 Preparation, characterization and in vitro transfection of nanocomplexes containing different cationic polyelectrolytes

[0154] (1) Preparation method 1:

[0155] ① Different types of cationic polyelectrolytes, EGFP mRNA, and hyaluronate HA (70 kDa) were co-incubated at a certain mass ratio (X:1:1, X=0, 2, 5, 20 or 50) to form a nucleic acid-loaded complex core.

[0156] ②Prepare liposomes by thin film hydration method: Weigh lipids (neutral lipid DOPE and anionic phospholipid DOPA), place in a 500mL round-bottom flask, add 2mL ether, evaporate to remove water from phospholipids, add 2mL chloroform solution, place on a rotary evaporator and evacuate for 1h. Add 4mL DEPC water, shake for 10min until the thin film is hydrated and falls off to obtain liposomes. Ultrasonic probe ultrasound further reduces the liposome particle size to obtain liposomes (LIPO).

[0157] ③ The liposomes and the nucleic acid-loaded complex cores are co-incubated in different proportions to form nanocomplexes encapsulating nucleic acid drugs.

[0158] (2) Characterization

[0159] The particle size and surface potential were measured by laser particle size analyzer.

[0160] (3) Evaluation of in vitro transfection effect

[0161] The experimental group and the control group (EGFP mRNA administration concentration was 2 μg / mL) were incubated with HEK293T cells at 37°C for 24 h. The transfection effect of the nanocomplex loaded with EGFP mRNA on HEK293T cells was observed by fluorescence microscopy, and the positive cell rate and mean fluorescence intensity were quantitatively counted by flow cytometry.

[0162] Experimental groups: ① Octa-arginine cyclic peptide CR8C was used as a cationic polyelectrolyte, represented by EGFP mRNA-HA-CR8C-LIPO (numbered A19 to A22); ② Monobasic protamine sulfate Protamine was used as a cationic polyelectrolyte, represented by EGFP mRNA-HA-Protamine-LIPO (numbered A23 to A26).

[0163] Control group: ①EGFP mRNA-HA-LIPO: nanocomplex without cationic polyelectrolyte (No. B32); ②EGFP mRNA-HA-CR8C: nanocomplex without lipid components and using CR8C as cationic electrolyte (No. B33~B36); ③EGFP mRNA-HA-Protamine: nanocomplex without lipid components and using Protamine as cationic electrolyte (No. B37~B40).

[0164] The test results are shown in Table 4. Figure 4 Part (A) and Figure 4 As shown in part (B).

[0165] Table 4 Quantitative results of nanocomposites containing different cationic polyelectrolytes

[0166]

[0167]

[0168] The results showed that nanocomplexes containing different cationic polyelectrolytes could achieve high levels of transfection on HEK293T cells. With the increase of cationic polyelectrolytes, the transfection efficiency showed a trend of first increasing and then decreasing. When CR8C was used as the cationic polyelectrolyte, the highest transfection efficiency was achieved when CR8C / EGFP mRNA=5 / 1. When Protamine was used as the cationic polyelectrolyte, the highest transfection efficiency was achieved when Protamine / EGFP mRNA=2 / 1.

[0169] Example 5 Preparation, characterization and in vitro transfection of nanocomplexes containing cationic polyelectrolytes with different degrees of polymerization

[0170] (1) Preparation method 1:

[0171] ① Cationic polyelectrolytes with different polymerization degrees, Luc mRNA, and hyaluronate HA (70 kDa) were co-incubated at a certain mass ratio (5:1:1 or 5:1:2) to form a nucleic acid-loaded complex core.

[0172] ②Prepare liposomes by thin film hydration method: Weigh lipids (neutral lipid DOPE and anionic phospholipid DOPA), place in a 500mL round-bottom flask, add 2mL ether, evaporate to remove water from phospholipids, add 2mL chloroform solution, place on a rotary evaporator and evacuate for 1h. Add 4mL DEPC water, shake for 10min until the thin film is hydrated and falls off to obtain liposomes. Ultrasonication with the ultrasonic probe further reduces the liposome particle size to obtain liposomes (LIPO).

[0173] ③ The liposomes and the nucleic acid-loaded complex cores are co-incubated in different proportions to form nanocomplexes encapsulating nucleic acid drugs.

[0174] (2) Characterization

[0175] The particle size and surface potential were measured by laser particle size analyzer.

[0176] (3) Evaluation of in vitro transfection effect

[0177] The transfection effect of the nanocomplex loaded with Luc mRNA on HEK293T cells was observed by small animal live imaging. After adding the luciferin substrate, the luciferase activity was characterized by the bioluminescence intensity to evaluate the transfection effect of the nanocomplex.

[0178] Experimental group: Polyarginine (poly Arg, octa-arginine linear peptide R8, deca-arginine linear peptide R10 and penta-arginine linear peptide R15) was used as the cationic polyelectrolyte, represented by Luc mRNA-HA-poly Arg-LIPO (numbered A27 to A32).

[0179] Control group: ①Luc mRNA-HA-LIPO: nanocomplex without cationic polyelectrolyte (No. B41); ②Luc mRNA-HA-poly Arg: nanocomplex without lipid components and with polyarginine of different polymerization degrees as cationic electrolyte (No. B42~B47).

[0180] The test results are shown in Table 5. Figure 5 shown.

[0181] Table 5 Quantitative results of cationic polyelectrolyte nanocomposites with different polymerization degrees

[0182]

[0183]

[0184] The results showed that cationic polyelectrolytes with different polymerization degrees could achieve high levels of transfection on HEK293T cells. When the content of cationic polyelectrolyte remained unchanged, the transfection efficiency increased with the increase of cationic polyelectrolyte polymerization degree. When polyarginine (poly Arg) was used as the cationic polyelectrolyte, the transfection efficiency was the highest when R15 / EGFPmRNA / HA=5 / 1 / 2.

[0185] Example 6 Preparation, characterization and in vitro transfection of nanocomplexes containing different anionic polyelectrolytes

[0186] (1) Preparation of Method 4:

[0187] ① Mix EGFP mRNA and different anionic polyelectrolytes in DEPC water at a fixed mass ratio (1:1).

[0188] ② Mix the octa-arginine cyclic peptide CR8C and phospholipids (neutral lipid DOPE and anionic phospholipid DOPA) in an ethanol solution.

[0189] ③ According to the volume ratio of water phase:alcohol phase = 4:1 and the total flow rate of 5 mL / min, a nanocomplex loaded with nucleic acid drugs was formed through a microfluidic chip.

[0190] (2) Characterization

[0191] The particle size and surface potential were measured by laser particle size analyzer.

[0192] (3) Evaluation of in vitro transfection effect

[0193] The experimental group and the control group (EGFP mRNA administration concentration was 2 μg / mL) were incubated with HEK293T cells at 37°C for 24 h. The transfection effect of the nanocomplex loaded with EGFP mRNA on HEK293T cells was observed by fluorescence microscopy, and the positive cell rate and mean fluorescence intensity were quantitatively counted by flow cytometry.

[0194] Experimental groups: ①EGFP mRNA-CR8C-LIPO: nanocomplex without anionic polyelectrolyte (number A33); ②Hyaluronic acid salt HA (70kDa) was used as anionic polyelectrolyte, represented by EGFP mRNA-HA-CR8C-LIPO (number A34~A42); ③Heparin sodium was used as anionic polyelectrolyte, represented by EGFP mRNA-Heparin-CR8C-LIPO. Among them, LIPO was the lipid component (number A43~A50).

[0195] Control group: ①EGFP mRNA-CR8C: nanocomplex without lipid components and anionic polyelectrolyte (No. B48); ②EGFP mRNA-HA-CR8C: nanocomplex without lipid components (No. B49~B57); ③EGFPmRNA-Heparin-CR8C: nanocomplex without lipid components (No. B58~B65).

[0196] The test results are shown in Table 6. Figure 6 Part (A) and Figure 6 As shown in part (B).

[0197] Table 6 Quantitative results of nanocomposites containing different anionic polyelectrolytes

[0198]

[0199]

[0200] The results showed that a small amount of hyaluronate HA and dalteparin sodium Heparin can significantly enhance the transfection effect. With the increase of hyaluronate HA and dalteparin sodium Heparin, the transfection efficiency showed a trend of first increasing and then decreasing. At the same time, with the increase of hyaluronate, the particle size gradually became smaller and the potential tended to be more negatively charged. When the anionic polyelectrolyte was HA or Heparin, the highest transfection efficiency was achieved when the anionic polyelectrolyte / EGFP mRNA=2 / 1; when the anionic polyelectrolyte content was further increased, the particle size and potential decreased, and the transfection effect decreased.

[0201] Example 7 Preparation, characterization and in vitro transfection of nanocomplexes containing anionic polyelectrolytes with different degrees of polymerization

[0202] (1) Preparation method 1:

[0203] ① The octa-arginine cyclic peptide CR8C, EGFP mRNA, and hyaluronate HA with different polymerization degrees were co-incubated at a certain mass ratio (5:1:x, X=0, 1 or 2) to form a nucleic acid-loaded complex core (EGFP mRNA-HA (kDa)-CR8C).

[0204] ②Prepare liposomes by thin film hydration method: Weigh lipids (neutral lipid DOPE and anionic phospholipid DOPA), place in a 500mL round-bottom flask, add 2mL ether, evaporate to remove water from phospholipids, add 2mL chloroform solution, place on a rotary evaporator and evacuate for 1h. Add 4mL DEPC water, shake for 10min until the thin film is hydrated and falls off to obtain liposomes. Ultrasonication with the ultrasonic probe further reduces the liposome particle size to obtain liposomes (LIPO).

[0205] ③ The liposomes were co-incubated with the nucleic acid-loaded complex core to form a nanocomplex containing nucleic acid drugs (EGFPmRNA-HA(kDa)-CR8C-LIPO).

[0206] (2) Characterization

[0207] The particle size and surface potential were measured by laser particle size analyzer.

[0208] (3) Evaluation of in vitro transfection effect

[0209] The experimental group and the control group (EGFP mRNA administration concentration was 2 μg / mL) were incubated with HEK293T cells at 37°C for 24 h. The transfection effect of the nanocomplex loaded with EGFP mRNA on HEK293T cells was observed by fluorescence microscopy, and the positive cell rate and mean fluorescence intensity were quantitatively counted by flow cytometry.

[0210] Experimental groups: ① Nanocomplexes without HA, represented by EGFP mRNA-CR8C-LIPO (number A51); ② Nanocomplexes containing hyaluronate HA with different polymerization degrees (10 kDa, 50 kDa, 100 kDa, 210 kDa, 700 kDa or 2200 kDa), represented by EGFP mRNA-HA (kDa)-CR8C-LIPO (numbers A52 to A63).

[0211] The test results are shown in Table 7 and Figure 7 shown.

[0212] Table 7 Quantitative results of nanocomposites containing hyaluronates with different degrees of polymerization

[0213]

[0214] The results showed that the addition of a certain amount of hyaluronate HA with different polymerization degrees could significantly enhance the transfection effect.

[0215] Example 8 Preparation of Nanocomplex and Its Transfection Effect in Different Cells

[0216] (1) Preparation of Method 4:

[0217] ① EGFP mRNA and hyaluronate HA (70 kDa) were mixed in DEPC water at a fixed mass ratio (1:1).

[0218] ② Mix the octa-arginine cyclic peptide CR8C and phospholipids (neutral lipid DOPE and anionic phospholipid DOPA) in an ethanol solution.

[0219] ③ According to the volume ratio of water phase:alcohol phase = 4:1 and the total flow rate of 5 mL / min, a nanocomplex loaded with nucleic acid drugs was formed through a microfluidic chip.

[0220] (2) Characterization

[0221] The particle size and surface potential were measured by laser particle size analyzer.

[0222] (3) Evaluation of intracellular transfection effect

[0223] Experimental group: EGFP mRNA-HA-CR8C-LIPO nanocomplex with DOPA as anionic phospholipid, where LIPO is the lipid component.

[0224] Control group: EGFP mRNA + commercial nucleic acid transfection reagent, namely EGFP mRNA-Lipofectamine 3000.

[0225] HEK293T cells, SH-SY5Y cells, HT-22 cells, HepG2 cells, HT1080 cells, BV2 cells and bEnd.3 cells were transfected with 400 ng (EGFP mRNA) / 96 well and incubated at 37°C for 24 hours. The transfection effect of the EGFP mRNA-loaded nanocomplex on HEK293T cells was observed by ordinary fluorescence microscopy, and the positive cell rate and mean fluorescence intensity were quantitatively counted by flow cytometry.

[0226] The results showed that the EGFP mRNA-HA-CR8C-LIPO formulation achieved high levels of transfection in HEK293T, SH-SY5Y, HT-22, HepG2, HT1080, BV2, and bEnd.3 cell lines (e.g. Figure 8), the transfection efficiency is close to or even exceeds that of the commercial nucleic acid transfection reagent Lipofectamine 3000. At the same time, it also shows the difference in transfection efficiency between different cell lines.

[0227] Example 9 Preparation and characterization of nanocomplexes loaded with different nucleic acid drugs and their in vitro and in vivo transfection

[0228] (1) Preparation of Method 4:

[0229] ① EGFP siRNA or EGFP pDNA and hyaluronate HA (70 kDa) were mixed in DEPC water at a fixed mass ratio (1:1).

[0230] ② Mix the octa-arginine cyclic peptide CR8C and phospholipids (neutral lipid DOPE and anionic phospholipid DOPA) in an ethanol solution.

[0231] ③ According to the volume ratio of water phase:alcohol phase = 4:1 and the total flow rate of 5 mL / min, a nanocomplex loaded with nucleic acid drugs was formed through a microfluidic chip.

[0232] (2) Characterization

[0233] The particle size and surface potential were measured by laser particle size analyzer.

[0234] (3) Evaluation of intracellular transfection effect (EGFP siRNA)

[0235] Experimental group: EGFP siRNA-HA-CR8C-LIPO: nanocomplex with EGFP siRNA as nucleic acid drug (No. A64), in which LIPO is the lipid component.

[0236] Control group: ① Blank group without any preparation added after DOX treatment (No. B66); ② Free EGFP siRNA (No. B67); ③ EGFP siRNA-LIPO: EGFP siRNA phospholipid mixture without HA and CR8C (No. B68); ④ EGFP siRNA-HA-CR8C: nanocomplex without lipid components (No. B69).

[0237] Doxycycline DOX (1 mg / mL) was diluted to 100 ng / mL with DMEM, and 150 μL was added to each 96-well to induce EGFP expression. Then, each group of preparations was added to the wells, and the final concentration of EGFP siRNA was 150 nM. The cells were incubated at 37°C for 48 hours, and the silencing effect of the nanocomplex loaded with EGFP siRNA on U2OS cells was observed by ordinary fluorescence microscopy, and the average fluorescence intensity was quantitatively counted by flow cytometry.

[0238] (4) Evaluation of in vitro transfection effect (EGFPpDNA)

[0239] Experimental group: EGFP pDNA-HA-CR8C-LIPO: nanocomplex with EGFP pDNA as nucleic acid drug (No. A65), in which LIPO is the lipid component.

[0240] Control group: ① free EGFP pDNA (No. B70); ② EGFP pDNA-LIPO: pDNA phospholipid mixture without HA and CR8C (No. B71); ③ EGFP pDNA-HA-CR8C: nanocomplex without lipid components (No. B72).

[0241] HEK293T cells were transfected with 400 ng (EGFP pDNA) / 96 wells and incubated at 37°C for 24 hours. The transfection effect of each group on HEK293T cells was observed by fluorescence microscopy, and the positive cell rate and average fluorescence intensity were quantitatively counted by flow cytometry.

[0242] The test results are shown in Table 8 and Fig. 9 Part (A) Fig. 9 As shown in part (B).

[0243] Table 8 Quantitative results of nanocomplexes loaded with different nucleic acid drugs

[0244]

[0245]

[0246] The results showed that EGFP siRNA-HA-CR8C-LIPO successfully knocked down EGFP in U2OS cells. EGFPpDNA-HA-CR8C-LIPO successfully delivered plasmid DNA in HEK293T cells. The above examples prove that in addition to delivering EGFP mRNA, the nanocomplex can also successfully deliver EGFP siRNA and EGFP pDNA, which has good versatility and universality.

[0247] Example 10 Preparation, characterization, in vitro transfection effects and in vitro toxicity of different nanocomplexes

[0248] (1) Preparation method 1:

[0249] ① The octa-arginine cyclic peptide CR8C, EGFP mRNA, and hyaluronate HA (50 kDa) were incubated at a fixed mass ratio (5:1:1) to form a nucleic acid-loaded complex (EGFP mRNA-HA-CR8C).

[0250] ②Prepare liposomes by thin film hydration method: Weigh lipids (neutral phospholipids DOPE and anionic phospholipids DOPA or DOPS), place in a 500mL round-bottom flask, add 2mL of ether, evaporate to remove water from phospholipids, add 2mL of chloroform solution, and place on a rotary evaporator to evacuate for 1h. Add 4mL of DEPC water and shake for 10min until the thin film is hydrated and falls off to obtain liposomes. Ultrasonic probe ultrasound further reduces the liposome particle size to obtain liposomes (LIPO).

[0251] ③ The liposomes were co-incubated with EGFP mRNA-HA-CR8C to prepare a nanocomplex containing nucleic acid drugs (EGFPmRNA-HA-CR8C-LIPO).

[0252] (2) Preparation of DLin-LNP

[0253] The above four groups of phospholipids were dissolved in ethanol according to the molar ratio of DLin-MC3-DMA / DSPC / Cholesterol / DMG-PEG=50:10:38.5:1.5, and EGFP mRNA was dissolved in 10mM citric acid-citrate buffer (pH=4.0). According to the ratio of water / alcohol=3 / 1 (vol. / vol.) and lipid / nucleic acid=40 / 1 (wt. / wt.), the aqueous phase was added to the alcohol phase, and the two phases were mixed evenly by blowing 20 times, and incubated at room temperature for 10 minutes. The alcohol was ultrafiltered by 30kDa ultrafiltration tube to reduce the ethanol concentration to less than 0.5%.

[0254] (3) Characterization

[0255] The particle size and surface potential were measured by laser particle size analyzer.

[0256] (4) Evaluation of in vitro transfection effect

[0257] The EGFP mRNA gradient concentration was set to 0, 100, 200, 400 and 600 ng / well, and the corresponding dosing concentrations were 0, 0.5, 1, 2 and 3 μg / mL. The transfection effect of the nanocomplex loaded with EGFP mRNA on HEK293T cells was observed by fluorescence microscopy, and the EGFP positive cell rate and average fluorescence intensity were quantitatively counted by flow cytometry. (Table 9 and Fig.10 (A)

[0258] Experimental group: DOPA and DOPS were used as anionic phospholipids to prepare nanocomplexes EGFP mRNA-HA-CR8C-LIPO (numbered A66 to A69).

[0259] Control group: ① The concentration of EGFP mRNA was 0 (No. B73); ② Lipid nanoparticles (LNPs) with DLin-MC3-DMA as ionizable phospholipids, namely EGFP mRNA-DLin-LNP (No. B75-B79).

[0260] (4) In vitro toxicity evaluation

[0261] Cell viability was detected by CCK8 reagent on HEK293T cells. (Table 9 and Fig.10 (B)

[0262] Experimental group: DOPA and DOPS were used as anionic phospholipids to prepare nanocomplexes EGFP mRNA-HA-CR8C-LIPO (numbered A70 to A73).

[0263] Control group: EGFP mRNA concentration was 0 (No. B74); ② Lipid nanoparticles (LNPs) with DLin-MC3-DMA as ionizable phospholipids, namely EGFP mRNA-DLin-LNP (No. B75~B79).

[0264] Table 9 Quantitative results of in vitro transfection and in vitro toxicity of different nanocomplexes

[0265]

[0266] The results showed that EGFP mRNA-HA-CR8C-LIPO showed a dose-dependent enhancement in transfection efficiency in vitro, and the EGFP-positive cell rate and average fluorescence intensity were much higher than those of EGFP mRNA-DLin-LNP. At the same time, EGFP mRNA-HA-CR8C-LIPO showed very low toxicity in vitro, and a dose of 200ng could even enhance cell viability, while a dose of 600ng showed lower cytotoxicity. EGFP mRNA-DLin-LNP showed a dose-dependent enhancement in cytotoxicity. When the dose was 600ng, the cell viability was only 66.8%, which was much lower than that of EGFP mRNA-HA-CR8C-LIPO. The results showed that the in vitro transfection effect and safety of EGFP mRNA-HA-CR8C-LIPO were better than those of EGFP mRNA-DLin-LNP.

[0267] Example 11 Preparation of Nanocomplex and Transfection Results in BALB / c Nude Mice

[0268] (1) Preparation by Method 2:

[0269] ① The octameric amino acid cyclic peptide CR8C or protamine sulfate protamine, Luc mRNA, and hyaluronate HA (50kDa) were incubated together in a certain mass ratio to form a nucleic acid-loaded complex core.

[0270] ②Prepare liposomes by thin film hydration method: Weigh lipids (neutral lipids DOPE and anionic phospholipids DOPA or DOPS), place in a 500mL round-bottom flask, add 2mL of ether, evaporate to remove water from phospholipids, add 2mL of chloroform solution, and place on a rotary evaporator to evacuate for 1h. Add 4mL of DEPC water and shake for 10min until the thin film is hydrated and falls off to obtain liposomes. Ultrasonication with the ultrasonic probe further reduces the particle size of the liposomes to obtain liposomes (LIPO).

[0271] ③ The liposomes and the nucleic acid-loaded complex core are rapidly mixed and co-incubated in a certain ratio through a microfluidic chip to form a nanocomplex containing nucleic acid drugs.

[0272] (2) In vivo drug administration and transfection effect evaluation:

[0273] ① Intraperitoneal injection:

[0274] Experimental group: Luc mRNA-HA-CR8C-LIPO (No. A74).

[0275] Control group: Luc mRNA-HA-CR8C: nanocomplex without lipid component (No. B81).

[0276] Dosage: 0.2 μg Luc mRNA / g;

[0277] Detection time: 6h;

[0278] Detection method: Intraperitoneal injection of 200 μL of 15 mg / mL D-luciferin potassium salt.

[0279] The results show (Table 10, Fig.11 (A) ), 6 hours after intraperitoneal injection, Luc mRNA-HA-CR8C-LIPO successfully achieved Luc mRNA transfection in the peritoneal cavity, and the transfected organs included the spleen and intestine. The fluorescence signal of the Luc mRNA-HA-CR8C group was close to that of the blank mice, and there was no obvious in vivo transfection effect, showing the importance of phospholipids for in vivo transfection.

[0280] ②Intravitreal injection:

[0281] Experimental group: Luc mRNA-HA-CR8C-LIPO (No. A74).

[0282] Control group: Luc mRNA-HA-CR8C: nanocomplex without lipid component (No. B81).

[0283] Dosage: 280ng Luc mRNA / eye;

[0284] Detection time: 6h;

[0285] Detection method: Intraperitoneal injection of 200 μL of 15 mg / mL D-luciferin potassium salt.

[0286] The results show (Table 10, Fig.11 (B) ), 6 hours after intravitreal injection, Luc mRNA-HA-CR8C-LIPO successfully achieved Luc mRNA transfection in the eyeball. However, the fluorescence signal of the Luc mRNA-HA-CR8C group was close to that of the blank mice, and there was no obvious in vivo transfection effect.

[0287] ③Intramuscular injection:

[0288] Experimental group: Luc mRNA-HA-Protamine-LIPO (No. A75).

[0289] Control group: ①LucmRNA: free nucleic acid drug (No. B80); ②LucmRNA-HA-Protamine: nanocomplex without lipid components (No. B82).

[0290] Dosage: 2.5 μg Luc mRNA / Leg;

[0291] Detection time: 24h;

[0292] Detection method: Intraperitoneal injection of 200 μL of 15 mg / mL D-luciferin potassium salt.

[0293] The results show (Table 10, Fig.11 (C) ), 24h after intramuscular injection, Luc mRNA-HA-Protamine-LIPO successfully achieved Luc mRNA transfection in the legs. However, the fluorescence signals of the Luc mRNA and Luc mRNA-HA-Protamine groups were close to those of blank mice, and there was no obvious in vivo transfection effect.

[0294] ④ Stereotaxic brain injection

[0295] Experimental group: Luc mRNA-HA-Protamine-LIPO (No. A75).

[0296] Control group: Luc mRNA: free nucleic acid drug (No. B80).

[0297] Dosage: 500 ng Luc mRNA / lateral ventricle;

[0298] Detection time: 24h;

[0299] Detection method: Intraperitoneal injection of 200 μL of 15 mg / mL D-luciferin potassium salt.

[0300] The results show (Table 10, Fig.11 (D) ), 24h after brain injection, Luc mRNA-HA-Protamine-LIPO successfully achieved Luc mRNA transfection in the brain, while the fluorescence signal of the Luc mRNA group was close to that of the blank mice, with no obvious in vivo transfection effect.

[0301] Table 10 Quantitative results of nanocomplex transfection in mice

[0302]

[0303] The above in vivo experiments prove that this nanocomplex can successfully achieve the delivery of Luc mRNA in vivo, including the abdominal cavity, eyeball, muscle and brain tissue, and has certain universality and versatility and high application value.

Claims

1. A nanocomposite, characterized in that: The nanocomplex comprises 0.5-30% nucleic acid drug, 0.5-95% cationic polyelectrolyte and 1.5-97% lipid component; the above percentages are the mass percentages of each component relative to the nanocomplex; The lipid components include electrically neutral lipids and anionic lipids; the electrically neutral lipids are neutral phospholipids containing primary amino head groups.

2. The nanocomposite according to claim 1, characterized in that The nucleic acid drug is one or more of siRNA, mRNA, sgRNA, pDNA, ASO and miRNA, preferably one or more of mRNA, siRNA and pDNA, such as mRNA, siRNA or pDNA; And / or, the cationic polyelectrolyte is a cationic polypeptide and / or a cationic protein; And / or, the neutral phospholipid containing a primary amino head group is one or more of dimyristoylphosphatidylethanolamine DMPE, distearoylphosphatidylethanolamine DSPE, dipalmitoylphosphatidylethanolamine DPPE, dioleoylphosphatidylethanolamine DOPE, dihexanoylphosphatidylethanolamine 06:0PE, didecanoylphosphatidylethanolamine 10:0PE, dilauroylphosphatidylethanolamine 12:0PE, 1-palmitoyl-2-oleoylphosphatidylethanolamine 16:0-18:1PE, 1-stearoyl-2-oleoylphosphatidylethanolamine 18:0-18:1PE, dilinoleoylphosphatidylethanolamine 18:2PE and derivatives thereof; And / or, the anionic lipid is an anionic phospholipid; And / or, the nanocomposite further comprises anionic polyelectrolyte; the anionic polyelectrolyte is preferably glycosaminoglycan and / or alginic acid.

3. The nanocomposite according to claim 2, characterized in that The following model nucleic acid drugs were used: and / or, the cationic polypeptide is an oligoarginine polypeptide, preferably one or more of octaarginine cyclic peptide CR8C, octaarginine linear peptide R8, decaarginine linear peptide R10 and 15-arginine linear peptide R15, such as octaarginine cyclic peptide CR8C, octaarginine linear peptide R8, decaarginine linear peptide R10 or 15-arginine linear peptide R15; And / or, the cationic protein is protamine; the protamine is preferably one or more of monoprotamine, diprotamine, ternary protamine and protamine hydrolysate; more preferably one or more of monoprotamine sulfate and its derivatives; and / or, the anionic phospholipid is one or more of phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, cardiolipin, lysophospholipid and ganglioside, preferably phosphatidic acid, phosphatidylglycerol or phosphatidylserine; And / or, the glycosaminoglycan is one or more of heparin, hyaluronic acid HA, chondroitin sulfate, keratan sulfate and dermatan sulfate, preferably heparin and / or hyaluronic acid.

4. The nanocomposite according to claim 3, characterized in that The phosphatidic acid is one or more of dimyristoylphosphatidic acid DMPA, distearoylphosphatidic acid DSPA, dipalmitoylphosphatidic acid DPPA, dioleoylphosphatidic acid DOPA, dihexanoylphosphatidic acid 06:0PA, didecanoylphosphatidic acid 10:0PA, dilauroylphosphatidic acid 12:0PA, 1-palmitoyl-2-oleoylphosphatidic acid 16:0-18:1PA, 1-stearoyl-2-oleoylphosphatidic acid 18:0-18:1PA, dilinoleoylphosphatidic acid 18:2PA, soybean phosphatidic acid SOYPA and derivatives thereof, such as dioleoylphosphatidic acid DOPA; And / or, the phosphatidylglycerol is one or more of dimyristoylphosphatidylglycerol DMPG, distearoylphosphatidylglycerol DSPG, dipalmitoylphosphatidylglycerol DPPG, dioleoylphosphatidylglycerol DOPG, dihexanoylphosphatidylglycerol 06:0PG, didecanoylphosphatidylglycerol 10:0PG, dilauroylphosphatidylglycerol 12:0PG, 1-palmitoyl-2-oleoylphosphatidylglycerol 16:0-18:1PG, 1-stearoyl-2-oleoylphosphatidylglycerol 18:0-18:1PG, dilinoleoylphosphatidylglycerol 18:2PG, egg yolk phosphatidylglycerol EPG and derivatives thereof, such as dioleoylphosphatidylglycerol DOPG; and / or, the phosphatidylserine is one or more of dimyristoylphosphatidylserine DMPS, dioleoylphosphatidylserine DOPS, dipalmitoylphosphatidylserine DPPS, dihexanoylphosphatidylserine 06:0PS, didecanoylphosphatidylserine 10:0PS, dilauroylphosphatidylserine 12:0PS, 1-palmitoyl-2-oleoylphosphatidylserine 16:0-18:1PS, 1-stearoyl-2-oleoylphosphatidylserine 18:0-18:1PS, dilinoleoylphosphatidylserine 18:2PS and distearoylphosphatidylserine DSPS, such as dioleoylphosphatidylserine DOPS; And / or, the heparin is one or more of ordinary heparin UFH, low molecular weight heparin LMWH, heparin derivatives, heparin analogs and derivatives thereof; the low molecular weight heparin is preferably dalteparin sodium; the heparin derivative is preferably fondaparinux sodium; the heparin analog is preferably danaparin; And / or, the hyaluronic acid is one or more of hyaluronate, oligomeric hyaluronic acid, non-cross-linked hyaluronic acid, cross-linked hyaluronic acid and derivatives thereof, such as hyaluronate; the molecular weight of the hyaluronate is preferably 3 to 2200 kDa, such as 10 kDa, 50 kDa, 70 kDa, 100 kDa, 210 kDa, 700 kDa or 2200 kDa.

5. The nanocomposite according to claim 1, characterized in that The nanocomplex does not include a cationic lipid; and / or, the nanocomplex does not include PEGylated phospholipids; And / or, the nanocomplex does not include apolipoprotein and / or its mimetic peptide.

6. The nanocomposite according to claim 1, characterized in that The dosage of the nucleic acid drug is 0.5-10%, for example, 0.83%, 1.41%, 1.50%, 1.52%, 2.19%, 2.63%, 2.72%, 2.75%, 3.00%, 3.26%, 3.38%, 3.44%, 3.48%, 3.74%, 3.89%, 4.05%, 4.22%, 4.29%, 4.34%, 4.36%, 4.40%, 4.41%, 4.44%, 4.46%, 4.48%, 4.52%, 4.53%, 4.54%, 4.59%, 4.61%, 4.62%, 4.64%, 5.34%, 5.77%, 6.52%, 6.97%, 6.98% or 9.37%; And / or, the amount of the cationic polyelectrolyte is 1-90%, preferably 4-75%, for example 4.14%, 7.07%, 7.59%, 10.69%, 10.94%, 13.13%, 13.73%, 14.99%, 16.28%, 17.20%, 17.41%, 18.72%, 19.45%, 20.23%, 21.09%, 21.43%, 21.68%, 21.80 %, 22.00%, 22.01%, 22.05%, 22.21%, 22.31%, 22.42%, 22.56%, 22.58%, 22.63%, 22.71%, 22.94%, 23.03%, 23.07%, 23.12%, 23.21%, 28.84%, 32.61%, 34.83%, 34.88%, 46.83%, 54.48% or 74.95%; And / or, the mass ratio of the cationic polyelectrolyte to the nucleic acid drug is (2-50):1, for example, 2:1, 5:1, 20:1 or 50:1; And / or, the mass ratio of the lipid component to the nucleic acid drug is (3-60):1, for example, 3.68:1, 7.33:1, 7.34:1, 7.35:1, 7.58:1, 14.55:1, 14.64:1, 14.67:1, 14.68:1, 14.69:1, 14.70:1, 14.71:1, 14.72:1, 14.74:1, 14.76: 1, 14.79:1, 14.89:1, 15.02:1, 15.08:1, 15.13:1, 15.19:1, 15.32:1, 15.35:1, 15.42:1, 15.52:1, 15.67:1, 15.73:1, 15.94:1, 16.05:1, 22.07:1, 29.37:1, 31.03:1 or 58.80:1; and / or, the molar ratio of the anionic lipid to the lipid component is (10-90):100, such as 10:100, 20:100, 40:100, 60:100, 80:100 or 90:100; and / or, the amount of the anionic lipid is 4-70%, for example 4.79%, 5.48%, 7.36%, 8.18%, 8.67%, 12.65%, 13.27%, 13.54%, 14.43%, 14.63%, 15.49%, 15.76%, 18.83%, 20.14%, 20.85%, 21.65%, 22.50%, 23.41%, 2 3.57%, 24.39%, 24.39%, 25.22%, 25.47%, 26.64%, 28.59%, 28.92%, 29.85%, 30.91%, 31.76%, 31.89%, 33.36%, 35.14%, 40.11%, 42.48%, 42.54%, 42.87%, 53.69%, 56.11% or 63.20%; And / or, the amount of the electrically neutral lipid is 6-70%, for example 6.45%, 7.40%, 12.63%, 12.98%, 13.09%, 13.38%, 13.81%, 15.94%, 19.53%, 20.13%, 20.90%, 21.46%, 24.26%, 24.32%, 25.95%, 26.43%, 27.52%, 29. .07%, 31.1%, 32.82%, 33.42%, 34.33%, 34.72%, 36.13%, 37.65%, 39.08%, 39.31%, 39.84%, 40.03%, 41.12%, 46.07%, 47.71%, 49.02%, 53.76%, 53.88%, 54.23%, 54.62 or 62.84%.

7. The nanocomposite according to claim 6, characterized in that The cationic polyelectrolyte is CR8C, and the mass ratio of CR8C to the nucleic acid drug is 5:1; And / or, the cationic polyelectrolyte is Protamine, and the mass ratio of Protamine to the nucleic acid drug is 2:1; And / or, the anionic lipid is DOPA, and the molar ratio of DOPA to the lipid component is (20-80):100, preferably (40-80):100, for example 40:100; And / or, the anionic lipid is DOPS, and the molar ratio of DOPS to the lipid component is (10-80):100, preferably (20-60):100, for example 20:100; And / or, the anionic lipid is DOPG, and the molar ratio of DOPG to the lipid component is (20-80):100, preferably (20-60):100, such as 40:

100.

8. The nanocomposite according to claim 1, characterized in that When the nanocomposite includes an anionic polyelectrolyte, the amount of the anionic polyelectrolyte is 0-95% and not 0, preferably 1.5-90%, more preferably 1.5-85%, for example 1.5%, 1.52%, 2.63%, 2.72%, 2.75%, 3.44%, 4.34%, 4.36%, 4.40%, 4.41%, 4.44%, 4.46%, 4.48%, 4.52%, 4.53%, 4.5 4%, 4.59%, 4.61%, 4.62%, 4.64%, 5.34%, 6.97%, 6.98%, 8.81%, 8.82%, 9.37%, 12.65%, 13.04%, 16.19%, 19.45%, 22.46%, 23.07%, 27.86%, 32.56%, 42.85%, 54.69%, 59.96%, 67.63%, 70.71% or 82.84%; And / or, when the nanocomposite includes anionic polyelectrolytes, the total amount of the anionic polyelectrolytes and cationic polyelectrolytes is 9-90%, for example, 9.11%, 13.41%, 15.76%, 16.03%, 16.48%, 20.64%, 26.02%, 26.16%, 26.40%, 26.46%, 26.65%, 26.71%, 26.77%, 26.90%, 27.03%, 27.10%, 27.16%, 27.25%, 27.49%, 27.5 3%, 27.64%, 27.68%, 27.74%, 27.85%, 30.82%, 31.38%, 33.74%, 36.42%, 38.90%, 41.18%, 41.80%, 41.86%, 45.27%, 45.65%, 48.84%, 51.91%, 55.98%, 56.20%, 57.20%, 59.09%, 64.28%, 65.63%, 67.63%, 74.95%, 76.45%, 77.78% or 86.95%; And / or, when the nanocomplex includes anionic polyelectrolytes, the mass ratio of the anionic polyelectrolyte to the nucleic acid drug is (1-100):1, for example, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 8:1, 10:1, 25:1, 50:1 or 100:1, preferably 2:

1.

9. A method for preparing the nanocomposite according to any one of claims 1 to 8, characterized in that: It is prepared by the following method 1, method 2, method 3, method 4 or method 5: Method 1: S1. The nucleic acid drug and the cationic polyelectrolyte are mixed to form a nucleic acid-loaded complex; S2. preparing liposomes by conventional methods using the lipid components; S3. The nucleic acid-loaded complex is co-incubated with the liposome to form a nucleic acid-loaded nanocomplex; Method 2: S1. The nucleic acid drug and the cationic polyelectrolyte are mixed to form a nucleic acid-loaded complex; S2. preparing liposomes by conventional methods using the lipid components; S3. The nucleic acid-loaded complex and the liposome are prepared by a microfluidic chip to carry out a nucleic acid-loaded nanocomposite; Method 3: S1. The nucleic acid drug and the cationic polyelectrolyte are mixed to form a nucleic acid-loaded complex; S2. preparing liposomes by conventional methods using the lipid components; S3. The nucleic acid-loaded complex and the liposome are extruded through a membrane to prepare a nucleic acid-loaded nanocomplex; Method 4: S1. The nucleic acid drug and the anionic polyelectrolyte are mixed in DEPC water; S2. The lipid component and the cationic polyelectrolyte are mixed in ethanol; S3. The aqueous phase and the alcohol phase are mixed to form a nanocomplex loaded with nucleic acid; Method 5: S1. The nucleic acid drug and the cationic polyelectrolyte are mixed to form a nucleic acid-loaded complex; S2. dissolving the lipid component in ethanol; S3. The nucleic acid-loaded complex is mixed with a lipid ethanol solution to form a nucleic acid-loaded nanocomplex.

10. Use of the nanocomplex according to any one of claims 1 to 8 in the preparation of a nucleic acid drug; preferably, the delivery target of the nucleic acid drug is inside a cell or in vivo; in, The cells are preferably HEK293T cells, SH-SY5Y cells, HT-22 cells, HepG2 cells, BV2 cells, bEnd.3 cells, U87 cells, GL261 cells, U2OS cells or HT1080 cells.